Eterna Therapeutics Inc
ERNA2.290USD
-0.080-3.38%
Close 06/13, 16:00（ET）Quotes delayed by 15 min
119.65MMarket Cap
LossP/E TTM
More Details of Ernexa Therapeutics Inc Company
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Company Info
Ticker SymbolERNA
Company nameErnexa Therapeutics Inc
IPO dateAug 29, 1991
Founded at1984
CEOMr. Sanjeev Luther
Number of employees6
Security typeOrdinary Share
Fiscal year-endAug 29
Address1035 Cambridge Street
CityCAMBRIDGE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02141
Phone16177986700
Websitehttps://www.ernexatx.com/
Ticker SymbolERNA
IPO dateAug 29, 1991
Founded at1984
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Feb 24
Currency: USDUpdated: Mon, Feb 24
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Subscription revenue
4.88M
84.17%
Other revenue
492.00K
8.48%
Hardware revenue
426.00K
7.34%
By RegionUSD
Name
Revenue
Proportion
United States
5.48M
94.48%
Canada
320.00K
5.52%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Subscription revenue
4.88M
84.17%
Other revenue
492.00K
8.48%
Hardware revenue
426.00K
7.34%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cherington (Charles)
37.73%
Freebird Partners LP
5.63%
Halpern (John D)
5.30%
Denny George P Iii
4.52%
Regolith Capital Investments LP
3.03%
Other
43.79%
Shareholders
Shareholders
Proportion
Cherington (Charles)
37.73%
Freebird Partners LP
5.63%
Halpern (John D)
5.30%
Denny George P Iii
4.52%
Regolith Capital Investments LP
3.03%
Other
43.79%
Shareholder Types
Shareholders
Proportion
Individual Investor
48.37%
Corporation
12.51%
Investment Advisor/Hedge Fund
0.55%
Investment Advisor
0.33%
Hedge Fund
0.27%
Research Firm
0.16%
Venture Capital
0.04%
Other
37.77%
Institutional Shareholding
Updated: Mon, Feb 24
Updated: Mon, Feb 24
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
53
40.16M
76.00%
+9.20M
2024Q4
54
33.02M
64.27%
+30.12M
2024Q3
67
2.84M
52.46%
-257.40K
2024Q2
83
2.52M
46.53%
-624.19K
2024Q1
121
2.54M
46.88%
-584.16K
2023Q4
126
2.36M
43.79%
-543.57K
2023Q3
142
2.77M
52.76%
-391.46K
2023Q2
146
2.77M
53.56%
-376.86K
2023Q1
150
2.98M
67.03%
+101.08K
2022Q4
155
3.12M
108.12%
+1.48M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cherington (Charles)
16.63M
31.84%
+5.08K
+0.03%
Mar 10, 2025
Freebird Partners LP
5.14M
8.26%
--
--
Mar 10, 2025
Halpern (John D)
5.14M
8.26%
--
--
Mar 10, 2025
Denny George P Iii
4.94M
7.95%
+4.48M
+979.96%
Mar 10, 2025
Regolith Capital Investments LP
2.48M
3.99%
+2.48M
--
Mar 10, 2025
IAF, LLC
2.68M
4.31%
--
--
Mar 10, 2025
Purchase Capital LLC
1.00M
1.61%
+1.00M
--
Dec 31, 2024
Singer (Nicholas Jason)
810.00K
1.3%
+810.00K
--
Dec 31, 2024
Geode Capital Management, L.L.C.
257.31K
0.41%
+236.88K
+1.16K%
Dec 31, 2024
Corient Private Wealth LLC
262.86K
0.42%
--
--
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
Date
Type
Ratio
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
